Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-023583
Filing Date
2026-06-01
Accepted
2026-06-01 17:00:21
Documents
4
Period of Report
2026-07-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20071594x2_def14a.htm DEF 14A 345302
2 logo_outlookthera.jpg GRAPHIC 52140
3 ny20071594x2_pc01.jpg GRAPHIC 767659
4 ny20071594x2_pc02.jpg GRAPHIC 457273
  Complete submission text file 0001140361-26-023583.txt   2104555
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 261052098
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)